<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment of community-acquired pneumonia in adults in the outpatient setting</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment of community-acquired pneumonia in adults in the outpatient setting</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Treatment of community-acquired pneumonia in adults in the outpatient setting</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Thomas M File, Jr, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Julio A Ramirez, MD, FACP</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sheila Bond, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul Dieffenbach, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 06, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Community-acquired pneumonia (CAP) is defined as an acute infection of the pulmonary parenchyma in a patient who has acquired the infection in the community, as distinguished from hospital-acquired (nosocomial) pneumonia (HAP).</p><p>CAP is a common and potentially serious illness [<a href="#rid1">1-3</a>]. It is associated with considerable morbidity and mortality, particularly in older adult patients and those with major comorbidities. (See  <a class="medical medical_review" href="/z/d/html/7016.html" rel="external">"Morbidity and mortality associated with community-acquired pneumonia in adults"</a>.)</p><p>The treatment of CAP in adults in the outpatient setting will be reviewed here. Other related issues are discussed separately: </p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7032.html" rel="external">"Clinical evaluation and diagnostic testing for community-acquired pneumonia in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7022.html" rel="external">"Community-acquired pneumonia in adults: Assessing severity and determining the appropriate site of care"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7027.html" rel="external">"Treatment of community-acquired pneumonia in adults who require hospitalization"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6993.html" rel="external">"Treatment of hospital-acquired and ventilator-associated pneumonia in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6990.html" rel="external">"Epidemiology, pathogenesis, and microbiology of community-acquired pneumonia in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7024.html" rel="external">"Aspiration pneumonia in adults"</a> and  <a class="medical medical_review" href="/z/d/html/1402.html" rel="external">"Epidemiology of pulmonary infections in immunocompromised patients"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/127759.html" rel="external">"COVID-19: Evaluation of adults with acute illness in the outpatient setting"</a> and  <a class="medical medical_review" href="/z/d/html/129312.html" rel="external">"COVID-19: Evaluation and management of adults with persistent symptoms following acute illness ("Long COVID")"</a> and  <a class="medical medical_review" href="/z/d/html/139068.html" rel="external">"COVID-19: Management of adults with acute illness in the outpatient setting"</a>.)</p><p></p><p class="headingAnchor" id="H2859760653"><span class="h1">DEFINITIONS</span><span class="headingEndMark"> — </span>CAP is defined as an acute infection of the pulmonary parenchyma in a patient who has acquired the infection in the community, as distinguished from hospital-acquired (nosocomial) pneumonia (HAP)  (<a class="graphic graphic_table graphicRef130821" href="/z/d/graphic/130821.html" rel="external">table 1</a>).</p><p>Health care-associated pneumonia (HCAP; no longer used) referred to pneumonia acquired in health care facilities (eg, nursing homes, hemodialysis centers) or after recent hospitalization [<a href="#rid4">4,5</a>]. The term HCAP was used to identify patients at risk for infection with multidrug-resistant pathogens. However, this categorization may have been overly sensitive, leading to increased, inappropriately broad antibiotic use and was thus retired [<a href="#rid6">6-10</a>].</p><p>Patients previously classified as having HCAP should be managed similarly to those with CAP, with the need for therapy targeting multidrug-resistant pathogens being considered on a case-by-case basis. Specific risk factors for resistance that should be assessed include recent receipt of antimicrobials, major comorbidities, functional status, and severity of illness [<a href="#rid11">11,12</a>].</p><p class="headingAnchor" id="H680556865"><span class="h1">INITIAL MANAGEMENT</span><span class="headingEndMark"> — </span>Obtaining an accurate diagnosis, determining the treatment setting, and starting antibiotic treatment promptly are essential early steps in CAP management.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Establishing the diagnosis</strong> – The diagnosis of CAP generally requires the demonstration of an infiltrate on chest imaging in a patient with a clinically compatible syndrome (eg, fever, dyspnea, cough, and sputum production). Because clinical features alone are nonspecific, obtaining a chest radiograph improves diagnostic accuracy and is considered a requirement for diagnosis by the Infectious Diseases Society of America (IDSA) and the American Thoracic Society (ATS) [<a href="#rid10">10</a>]. (See  <a class="medical medical_review" href="/z/d/html/7032.html" rel="external">"Clinical evaluation and diagnostic testing for community-acquired pneumonia in adults", section on 'Chest imaging findings'</a>.)</p><p></p><p class="bulletIndent1">While the combination of a compatible clinical syndrome and imaging findings consistent with pneumonia are sufficient to establish an initial working diagnosis of CAP and to start empiric antibiotic therapy, this combination of findings is nonspecific and is shared among many cardiopulmonary disorders. Thus, remaining attentive to the possibility of an alternate diagnosis as a patient's course evolves is important to care.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Determining the site of care</strong> – Determining whether a patient with CAP can be safely treated as an outpatient or requires hospital admission is an essential first step in management, which informs downstream diagnostic and therapeutic decisions  (<a class="graphic graphic_algorithm graphicRef113076" data-inline-graphics="113076" href="/z/d/graphic/113076.html" rel="external">algorithm 1</a>).</p><p></p><p class="bulletIndent1">While severity of illness is the key determinant, other factors should also be taken into account. These include the ability to maintain oral intake, likelihood of medication adherence, history of active substance abuse, mental illness, cognitive or functional impairment, and living or social circumstances (eg, homelessness, residence far enough from a health care facility that precludes timely return to care in the event of clinical worsening). (See  <a class="medical medical_review" href="/z/d/html/7022.html" rel="external">"Community-acquired pneumonia in adults: Assessing severity and determining the appropriate site of care", section on 'Approach to site of care'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Microbiologic testing</strong> – For most patients with mild CAP being treated in the ambulatory setting, microbiologic testing is not needed  (<a class="graphic graphic_table graphicRef118966" href="/z/d/graphic/118966.html" rel="external">table 2</a>) [<a href="#rid10">10</a>]. Empiric antibiotic therapy is generally successful, and knowledge of the infecting pathogen does not usually improve outcomes [<a href="#rid13">13</a>]. However, when clinical suspicion for a specific pathogen is high based on clinical and/or epidemiologic features (eg, high activity of influenza in the community, during outbreaks), microbiologic testing can be helpful, particularly when treatment of the suspect pathogen differs from standard empiric therapy or when there are public health implications.</p><p></p><p class="bulletIndent1">Important pathogens to bear in mind when considering the need to test include <em>Legionella</em> species, <em>Mycobacterium tuberculosis</em>, influenza A and B, avian influenza, Middle East respiratory syndrome coronavirus, community-acquired methicillin-resistant <em>Staphylococcus aureus</em> (CA-MRSA), or agents of bioterrorism. Advances in molecular testing for etiology may allow for earlier pathogen-directed therapy than was previously possible.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Timing of treatment</strong> – Since patients who do not require admission are often not given the first dose of antibiotics when they present for care, they should be counseled to fill their prescription without delay in order to achieve the best outcome. Specific treatment regimens are discussed below. (See <a class="local">'Preferred agents'</a> below.)</p><p></p><p class="headingAnchor" id="H11"><span class="h1">EMPIRIC ANTIBIOTIC TREATMENT</span></p><p class="headingAnchor" id="H2787226612"><span class="h2">General approach</span><span class="headingEndMark"> — </span>Empiric regimens are designed to cover the most common bacterial causes of CAP encountered in the outpatient setting  (<a class="graphic graphic_table graphicRef72014" href="/z/d/graphic/72014.html" rel="external">table 3</a>).</p><p class="bulletIndent1"><span class="glyph">●</span>For all patients, our empiric regimens target <em>Streptococcus pneumoniae,</em> <em>Haemophilus influenzae</em>, and atypical pathogens (ie, <em>Mycoplasma pneumoniae, Legionella pneumophila</em>, and <em>Chlamydia pneumoniae</em>). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Coverage is expanded to include or better treat certain gram-negative pathogens (eg, beta-lactamase-producing <em>H. influenzae</em>, <em>Moraxella catarrhalis,</em> and methicillin-susceptible <em>S. aureus</em> for older patients, smokers, and those with comorbidities (eg, chronic heart, lung, liver, or kidney disease, diabetes mellitus, alcohol use disorder) and/or recent antibiotic use.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with structural lung disease (eg, advanced chronic obstructive pulmonary disease [COPD]), we also select a regimen that includes coverage for Enterobacteriaceae (eg, <em>Escherichia coli</em> and <em>Klebsiella</em> spp).</p><p></p><p>The backbone of therapy is the beta-lactam, which primarily targets <em>S. pneumoniae</em>. Among beta-lactams, high-dose <a class="drug drug_general" data-topicid="8673" href="/z/d/drug information/8673.html" rel="external">amoxicillin</a> and <a class="drug drug_general" data-topicid="8676" href="/z/d/drug information/8676.html" rel="external">amoxicillin-clavulanate</a> are preferred because they remain active against most strains of <em>S. pneumoniae</em>, despite rising resistance rates among macrolides, tetracyclines, and other antibiotic classes. We generally use amoxicillin-clavulanate rather than amoxicillin in older patients, smokers, and those with comorbidities because of its extended spectrum.</p><p>Generally, we add either a macrolide or <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> to the beta-lactam to target atypical pathogens. However, the value of treating atypical pathogens in otherwise healthy patients is debated [<a href="#rid10">10,14,15</a>]. Specifically, our approach differs from the American Thoracic Society/Infectious Diseases Society of America (ATS/IDSA) with regard to covering atypical pathogens in all patients  (<a class="graphic graphic_table graphicRef142676" href="/z/d/graphic/142676.html" rel="external">table 4</a>). The ATS/IDSA recommends including coverage for atypical pathogens for all patients except outpatients who are otherwise healthy, aged &lt;65 years old, and have not recently used antibiotics. (See <a class="local">'Comorbidities, age 65 years or older, or recent antibiotic use'</a> below.)</p><p>Respiratory viruses (eg, influenza, parainfluenza, respiratory syncytial virus) are also among the most frequently detected causes of CAP and may occur concurrently or independently from bacterial infection. When influenza virus is a confirmed or suspected cause of CAP, antiviral treatment is typically warranted. (See  <a class="medical medical_review" href="/z/d/html/6998.html" rel="external">"Seasonal influenza in nonpregnant adults: Treatment"</a>.)</p><p>Although a wide variety of other pathogens can cause CAP, these few described above are responsible for the majority of cases with a known cause in the outpatient setting. Other bacterial causes of CAP, such as MRSA, Enterobacteriaceae, and <em>Pseudomonas aeruginosa</em>, tend to be associated with greater illness severity and are detected more frequently in hospitalized patients and those with specific risk factors. (See  <a class="medical medical_review" href="/z/d/html/7027.html" rel="external">"Treatment of community-acquired pneumonia in adults who require hospitalization", section on 'Likely pathogens'</a> and  <a class="medical medical_review" href="/z/d/html/6990.html" rel="external">"Epidemiology, pathogenesis, and microbiology of community-acquired pneumonia in adults"</a>.)</p><p class="headingAnchor" id="H1686793121"><span class="h2">Preferred agents</span><span class="headingEndMark"> — </span>No first-line empiric antibiotic regimen has been clearly shown to be superior to another for the empiric treatment of CAP in outpatients in clinical trials [<a href="#rid10">10,16</a>]. Thus, antibiotic selection depends on the likelihood of antibiotic resistance, patient comorbidities, and the potential for adverse medication effects (including drug hypersensitivity reactions)  (<a class="graphic graphic_algorithm graphicRef111829" data-inline-graphics="111829" href="/z/d/graphic/111829.html" rel="external">algorithm 2</a>). <span class="utd-adt-cnt utd-adt-pathwys utd-content-120483">(Related Pathway(s):  <a class="utd-content-120483" href="/pathway/120483?topicRef=7031&amp;source=see_link">Community-acquired pneumonia: Empiric antibiotic selection for adults in the outpatient setting</a>.)</span></p><p>Specific regimens are outlined below. Modifications to these regimens may be needed based on patient travel and exposure history, local epidemiology (eg, outbreaks, family clusters), or when specific pathogens are suspected (eg, influenza viruses, CA-MRSA, <em>M. tuberculosis</em>). The doses given below are intended for patients with normal renal and hepatic function; the doses of certain agents should be reduced in patients with organ dysfunction.</p><p class="headingAnchor" id="H2756779124"><span class="h3">Healthy, age &lt;65 years, no recent antibiotic use</span><span class="headingEndMark"> — </span>For otherwise healthy patients aged &lt;65 years who have not recently used antibiotics, we typically use an empiric regimen that targets <em>S. pneumoniae</em>, <em>H. influenzae</em>, and atypical pathogens (ie, <em>M. pneumoniae</em>, <em>L. pneumophila</em>, and <em>C. pneumoniae</em>)  (<a class="graphic graphic_algorithm graphicRef111829" href="/z/d/graphic/111829.html" rel="external">algorithm 2</a>).</p><p class="bulletIndent1"><span class="glyph">●</span>For most patients in this category, we treat with high-dose <a class="drug drug_general" data-topicid="8673" href="/z/d/drug information/8673.html" rel="external">amoxicillin</a> (1 g orally three times daily) plus either a macrolide (ie, <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a>, <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">clarithromycin</a>) or <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a>. Macrolides are generally preferred over doxycycline, unless there are contraindications. (See <a class="local">'Caveats for fluoroquinolones and macrolides'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with mild non-immunoglobulin (Ig)E-mediated reactions to penicillin (eg maculopapular rash) or known tolerance to cephalosporins, a third-generation cephalosporin (eg, <a class="drug drug_general" data-topicid="9224" href="/z/d/drug information/9224.html" rel="external">cefpodoxime</a>) is the preferred alternative to <a class="drug drug_general" data-topicid="8673" href="/z/d/drug information/8673.html" rel="external">amoxicillin</a>. Like amoxicillin, we give the cephalosporin in combination with an agent that targets atypical pathogens. For patients with IgE-mediated reactions (eg, urticaria, angioedema, anaphylaxis) or severe delayed reactions, empiric use of cephalosporins should generally be avoided. (See  <a class="medical medical_review" href="/z/d/html/2073.html" rel="external">"Penicillin allergy: Immediate reactions"</a> and  <a class="medical medical_review" href="/z/d/html/100191.html" rel="external">"Penicillin allergy: Delayed hypersensitivity reactions"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>When the above regimens cannot be used, we generally treat with a respiratory fluoroquinolone (ie, <a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">levofloxacin</a>, <a class="drug drug_general" data-topicid="10311" href="/z/d/drug information/10311.html" rel="external">moxifloxacin</a>, <a class="drug drug_general" data-topicid="8760" href="/z/d/drug information/8760.html" rel="external">gemifloxacin</a>). We have begun to adopt <a class="drug drug_general" data-topicid="122343" href="/z/d/drug information/122343.html" rel="external">lefamulin</a> monotherapy into practice, particularly for patients who cannot tolerate beta-lactams and wish to avoid the potential adverse effects associated with fluoroquinolones [<a href="#rid17">17,18</a>]. However, clinical experience with lefamulin is limited and use may be limited by cost and/or availability. Lefamulin has a more targeted spectrum for standard CAP patients than the fluoroquinolones but does not cover Enterobacteriaceae. Use should be avoided in patients with moderate to severe hepatic dysfunction, known long QT syndrome, or in those taking QT-prolonging agents, pregnant and breastfeeding women, and women with reproductive potential not using contraception. There are drug interactions with CYP3A4 and P-gp inducers and substrates; in addition, lefamulin tablets are contraindicated with QT-prolonging CYP3A4 substrates. Refer to the <a class="external" href="/drug-interactions">drug interactions program</a> included within UpToDate. (See  <a class="medical medical_review" href="/z/d/html/7027.html" rel="external">"Treatment of community-acquired pneumonia in adults who require hospitalization", section on 'New antimicrobial agents'</a>.)</p><p></p><p class="headingAnchor" id="H3859061955"><span class="h3">ATS/IDSA guidelines</span><span class="headingEndMark"> — </span>Our overall approach to empiric therapy for patients with CAP is similar to that outlined in the 2019 American Thoracic Society (ATS)/Infectious Diseases Society of America (IDSA) guidelines [<a href="#rid10">10</a>]. However, we differ in our treatment approach for outpatients who lack comorbidities or risk factors for drug resistance  (<a class="graphic graphic_table graphicRef142676" href="/z/d/graphic/142676.html" rel="external">table 4</a>). The ATS/IDSA guidelines recommend monotherapy with <a class="drug drug_general" data-topicid="8673" href="/z/d/drug information/8673.html" rel="external">amoxicillin</a> as first-line treatment; monotherapy with either <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> or a macrolide (if local macrolide-resistant <em>S. pneumoniae</em> rates are &lt;25 percent) are suggested alternates. Amoxicillin is preferred over other agents because <em>S. pneumoniae </em>is the primary relevant bacterial pathogen in this setting, and rates of resistance to doxycycline and macrolides among <em>S. pneumoniae</em> are growing. For macrolides, resistance rates among <em>S. pneumoniae</em> are often &gt;30 percent in the United States and typically &gt;25 percent for most parts of the world, apart from some regions in Northern Europe. For doxycycline, resistance rates are less well established but are approximately 10 to 20 percent in the United States and likely rising. Although atypical pathogens are less prominent causes of CAP, they have accounted for 22 percent of cases in some studies [<a href="#rid18">18</a>]. (See  <a class="medical medical_review" href="/z/d/html/7033.html" rel="external">"Resistance of <i>Streptococcus pneumoniae</i> to the macrolides, azalides, and lincosamides"</a> and  <a class="medical medical_review" href="/z/d/html/7034.html" rel="external">"Resistance of <i>Streptococcus pneumoniae</i> to beta-lactam antibiotics"</a> and  <a class="medical medical_review" href="/z/d/html/7028.html" rel="external">"Resistance of <i>Streptococcus pneumoniae</i> to the fluoroquinolones, doxycycline, and trimethoprim-sulfamethoxazole"</a>.)</p><p>We agree with the preference for <a class="drug drug_general" data-topicid="8673" href="/z/d/drug information/8673.html" rel="external">amoxicillin</a> over other agents but prefer to add an agent that also targets atypical pathogens because there is a potential morbidity benefit and the downside of a short course of therapy for most patients is low. Unfortunately, there are little data to inform outpatient practice in this regard. Trials performed in hospitalized patients with CAP suggest that the addition of atypical coverage improves time to clinical stability and decreases clinical failure rates, particularly among patients ultimately diagnosed with pneumonia due to an atypical pathogen and those with more severe pneumonia [<a href="#rid19">19-21</a>]. Because pneumonia caused by atypical pathogens can be severe and cannot be clearly distinguished from other types of pneumonia at the time of diagnosis, we generally favor empiric treatment with a regimen that includes treatment for atypical pathogens for all outpatients as well. (See  <a class="medical medical_review" href="/z/d/html/7027.html" rel="external">"Treatment of community-acquired pneumonia in adults who require hospitalization", section on 'Atypical bacteria'</a>.)</p><p class="headingAnchor" id="H2988812734"><span class="h3">Comorbidities, age 65 years or older, or recent antibiotic use</span><span class="headingEndMark"> — </span>For patients with major comorbidities (ie, chronic pulmonary, liver, heart, or renal disease, cancer, diabetes, congestive heart failure, alcohol dependence, immunosuppression), smokers, or those who have used antibiotics within the prior three months, we expand coverage to better treat beta-lactamase-producing <em>H. influenzae, M. catarrhalis, </em>and methicillin-susceptible <em>S. aureus</em> in addition to <em>S. pneumoniae </em>and atypical pathogens. For those with structural lung disease, we further expand coverage to treat Enterobacteriaceae (eg, <em>E. coli, Klebsiella </em>spp)  (<a class="graphic graphic_algorithm graphicRef111829" href="/z/d/graphic/111829.html" rel="external">algorithm 2</a>) [<a href="#rid10">10,22</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>For most patients in this category, we treat with <a class="drug drug_general" data-topicid="8676" href="/z/d/drug information/8676.html" rel="external">amoxicillin-clavulanate</a> (875 mg orally twice daily or the extended-release formulation dose at 2 g orally twice daily) plus a macrolide (ie, <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a>, <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">clarithromycin</a>) or <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a>. In general, we prefer macrolides over doxycycline because their use has been associated with improved outcomes in patients with more severe CAP (possibly due to their immunomodulatory effect) [<a href="#rid23">23-26</a>]. However, for patients who have contraindications to macrolides (eg, risk for or known prolonged QTc, allergy), doxycycline is an appropriate alternative. (See <a class="local">'Caveats for fluoroquinolones and macrolides'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>When <a class="drug drug_general" data-topicid="8676" href="/z/d/drug information/8676.html" rel="external">amoxicillin-clavulanate</a> cannot be used (eg, due to allergy or other intolerance), a third-generation cephalosporin, such as <a class="drug drug_general" data-topicid="9224" href="/z/d/drug information/9224.html" rel="external">cefpodoxime</a>, is our preferred alternative. As with amoxicillin-clavulanate, cephalosporins should be given in combination with either a macrolide or <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a>. In general, patients with mild non-IgE-mediated reactions (eg, maculopapular rash) to penicillin can generally use third-generation cephalosporins safely. Patients with IgE-mediated reactions (hives, angioedema, anaphylaxis) or severe delayed reactions should generally use other agents. (See  <a class="medical medical_review" href="/z/d/html/2073.html" rel="external">"Penicillin allergy: Immediate reactions"</a> and  <a class="medical medical_review" href="/z/d/html/100191.html" rel="external">"Penicillin allergy: Delayed hypersensitivity reactions"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Despite its greater convenience, we reserve monotherapy with respiratory fluoroquinolone (<a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">levofloxacin</a>, <a class="drug drug_general" data-topicid="10311" href="/z/d/drug information/10311.html" rel="external">moxifloxacin</a>, <a class="drug drug_general" data-topicid="8760" href="/z/d/drug information/8760.html" rel="external">gemifloxacin</a>) for patients who cannot tolerate either of the above regimens (eg, due to IgE-mediated or severe, delayed hypersensitivity reactions to penicillin) because of its adverse effect profile and the potential of promoting fluoroquinolone resistance. (See <a class="local">'Caveats for fluoroquinolones and macrolides'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We have also begun to adopt <a class="drug drug_general" data-topicid="122343" href="/z/d/drug information/122343.html" rel="external">lefamulin</a> monotherapy into practice, particularly for patients without structural lung disease (eg, advanced COPD) who cannot tolerate beta-lactams and wish to avoid the potential adverse effects associated with fluoroquinolones [<a href="#rid17">17,18</a>]. However, clinical experience with lefamulin is limited, use may be limited by cost and/or availability, and it does not cover Enterobacteriaceae. Use should be avoided in patients with moderate to severe hepatic dysfunction, known long QT syndrome, or in those taking QT-prolonging agents, pregnant and breastfeeding women, and women with reproductive potential not using contraception. There are drug interactions with CYP3A4 and P-gp inducers and substrates; in addition, lefamulin tablets are contraindicated with QT-prolonging CYP3A4 substrates. Refer to the <a class="external" href="/drug-interactions">drug interactions program</a> included within UpToDate. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="119253" href="/z/d/drug information/119253.html" rel="external">Omadacycline</a> is another newer agent that is active against most CAP pathogens, including Enterobacteriaceae. It is a potential alternative for patients who cannot tolerate beta-lactams (or other agents) and want to avoid fluoroquinolones. Studies that support its use have been performed in hospitalized patients. (See  <a class="medical medical_review" href="/z/d/html/7027.html" rel="external">"Treatment of community-acquired pneumonia in adults who require hospitalization", section on 'New antimicrobial agents'</a>.)</p><p></p><p class="headingAnchor" id="H846530329"><span class="h3">ATS/IDSA guidelines</span><span class="headingEndMark"> — </span>Our overall approach to empiric therapy for patients with CAP is similar to that outlined in the 2019 American Thoracic Society/Infectious Diseases Society of America (ATS/IDSA) guidelines [<a href="#rid10">10</a>]. However, we prefer to use an amoxicillin-clavulanate-based regimen because <a class="drug drug_general" data-topicid="8676" href="/z/d/drug information/8676.html" rel="external">amoxicillin-clavulanate</a> has reliable activity against <em>S. pneumoniae</em> and an overall favorable adverse effect profile. By contrast, the ATS/IDSA guidelines do not state a preference among beta-lactams nor between beta-lactam-based regimens and fluoroquinolone monotherapy  (<a class="graphic graphic_table graphicRef142676" href="/z/d/graphic/142676.html" rel="external">table 4</a>). In a systematic review of 11 randomized trials evaluating &gt;3300 adults and adolescents with CAP treated in the outpatient setting, clinical cure rates were similar when comparing various treatment regimens, including macrolides, fluoroquinolones, and beta-lactams [<a href="#rid16">16</a>]. However, most included trials were small and many evaluated medications that are no longer available. Data from the inpatient setting are more robust and suggest that the overall efficacy of combination beta-lactam-macrolide therapy and fluoroquinolone monotherapy is similar [<a href="#rid27">27-29</a>]. (See  <a class="medical medical_review" href="/z/d/html/7027.html" rel="external">"Treatment of community-acquired pneumonia in adults who require hospitalization"</a>.)</p><p class="headingAnchor" id="H3830317465"><span class="h2">Caveats for fluoroquinolones and macrolides</span><span class="headingEndMark"> — </span>Although fluoroquinolones are frequently used for treatment of CAP, their use is discouraged in ambulatory patients with CAP without comorbid conditions or recent antimicrobial use unless use of other regimens is not feasible.</p><p>There is concern that widespread use of fluoroquinolones in outpatients will promote the development of fluoroquinolone resistance among respiratory pathogens (as well as other colonizing pathogens) and may lead to an increased incidence of <em>Clostridioides</em> <em>difficile</em> colitis [<a href="#rid30">30</a>]. In addition, empiric use of fluoroquinolones should not be used for patients at risk for <em>M. tuberculosis</em> without an appropriate assessment for tuberculosis infection. The administration of a fluoroquinolone in patients with tuberculosis has been associated with a delay in diagnosis, increase in resistance, and poor outcomes. Despite these caveats about fluoroquinolones, they continue to be given, often inappropriately, for CAP [<a href="#rid13">13</a>]. (See  <a class="medical medical_review" href="/z/d/html/2696.html" rel="external">"<i>Clostridioides difficile </i>infection in adults: Epidemiology, microbiology, and pathophysiology", section on 'Antibiotic use'</a>.)</p><p>Macrolides, <a class="drug drug_general" data-topicid="122343" href="/z/d/drug information/122343.html" rel="external">lefamulin</a>, and fluoroquinolones can cause a prolonged QT interval, which can result in torsades de pointes. Studies assessing the risk-benefit ratio of <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a> are reviewed elsewhere (see  <a class="medical medical_review" href="/z/d/html/474.html" rel="external">"Azithromycin and clarithromycin", section on 'QT interval prolongation and cardiovascular events'</a>). For outpatients with known QT interval prolongation and for those considered to be at high risk of QT interval prolongation, we favor <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> since it is not associated with QT interval prolongation. However, doxycycline should be avoided during pregnancy. It should also be noted that doxycycline has been less well studied for the treatment of CAP than the macrolides or fluoroquinolones. Risk factors for QT interval prolongation include advanced age, hypokalemia, hypomagnesemia, clinically significant bradycardia, and the use of other agents that prolong the QT interval, including class IA (<a class="drug drug_general" data-topicid="9846" href="/z/d/drug information/9846.html" rel="external">quinidine</a>, <a class="drug drug_general" data-topicid="9813" href="/z/d/drug information/9813.html" rel="external">procainamide</a>) and class III (<a class="drug drug_general" data-topicid="8904" href="/z/d/drug information/8904.html" rel="external">dofetilide</a>, <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">amiodarone</a>, <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">sotalol</a>) antiarrhythmic agents and certain azoles (eg, <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">voriconazole</a>, <a class="drug drug_general" data-topicid="9479" href="/z/d/drug information/9479.html" rel="external">posaconazole</a>). (See  <a class="medical medical_review" href="/z/d/html/1043.html" rel="external">"Acquired long QT syndrome: Definitions, pathophysiology, and causes"</a> and  <a class="medical medical_review" href="/z/d/html/495.html" rel="external">"Pharmacology of azoles", section on 'Selected clinical effects'</a> and  <a class="medical medical_review" href="/z/d/html/474.html" rel="external">"Azithromycin and clarithromycin", section on 'QT interval prolongation and cardiovascular events'</a> and  <a class="medical medical_review" href="/z/d/html/490.html" rel="external">"Fluoroquinolones", section on 'QT interval prolongation'</a>.)</p><p class="headingAnchor" id="H2776900527"><span class="h1">PATHOGEN-DIRECTED THERAPY</span><span class="headingEndMark"> — </span>Pathogen-directed therapy is less common in the outpatients setting because microbiologic testing is typically not preformed (apart from coronavirus disease 2019 [COVID-19] testing during the pandemic). However, as molecular diagnostics become increasingly available and both cost and turnaround time decrease, microbiologic diagnoses are being more frequently made in ambulatory patients. (See  <a class="medical medical_review" href="/z/d/html/7032.html" rel="external">"Clinical evaluation and diagnostic testing for community-acquired pneumonia in adults", section on 'Microbiologic testing'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bacterial CAP</strong> – If a bacterial cause of CAP has been identified using reliable microbiologic methods, antimicrobial therapy should be directed at that pathogen  (<a class="graphic graphic_table graphicRef64816" href="/z/d/graphic/64816.html" rel="external">table 5</a>). Directed therapy for selected bacterial pathogens is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7013.html" rel="external">"Pneumococcal pneumonia in patients requiring hospitalization"</a> and  <a class="medical medical_review" href="/z/d/html/6989.html" rel="external">"<i>Mycoplasma pneumoniae</i> infection in adults"</a> and  <a class="medical medical_review" href="/z/d/html/7036.html" rel="external">"Pneumonia caused by <i>Chlamydia pneumoniae</i> in adults"</a> and  <a class="medical medical_review" href="/z/d/html/7025.html" rel="external">"Treatment and prevention of <i>Legionella</i> infection"</a> and  <a class="medical medical_review" href="/z/d/html/3133.html" rel="external">"Pseudomonas aeruginosa pneumonia"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Viral CAP</strong> – Deciding whether to stop empiric antibiotic therapy for outpatients when a virus has been detected on testing is challenging. The approach varies among experts and is generally based on the specific virus detected, the certainty that the virus is the sole pathogen, and patient characteristics (eg, severity of illness, risk factors for poor outcomes, ability to follow-up closely). </p><p></p><p class="bulletIndent1">For patients who are diagnosed with a virus that is known to cause pneumonia (eg, influenza), who do not have chest imaging findings that suggest bacterial superinfection (eg, lobar consolidation or alveolar consolidation), and at least one other objective factor that indicates a bacterial infection is unlikely (eg, procalcitonin &lt;0.25 ng/dL, negative sputum cultures, negative respiratory pathogen panel [ie, multiplex polymerase chain reaction testing for bacterial and respiratory pathogens]), it is reasonable to withhold antibiotics provided that close follow-up can be arranged. A normal white blood cell count also makes the diagnosis of bacterial pneumonia less likely, though this is nonspecific. When resources for testing are not available or when it is uncertain whether the virus is the sole pathogen, we continue antibiotics because bacterial coinfection carries the risk of substantial morbidity. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>COVID-19</strong> – Patients with COVID-19 and pneumonia should generally be hospitalized and treated with COVID-19 specific therapy, especially those who need supplemental oxygen (eg, <a class="drug drug_general" data-topicid="127259" href="/z/d/drug information/127259.html" rel="external">remdesivir</a>, glucocorticoids). Because bacterial superinfection appears to be less common in patients with COVID-19 than with other viruses, our threshold to initiate antibiotic therapy or stop it early is lower than with other viral infections. This is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/127429.html" rel="external">"COVID-19: Management in hospitalized adults", section on 'Empiric treatment for bacterial pneumonia in selected patients'</a>.)</p><p></p><p class="headingAnchor" id="H3859450007"><span class="h1">LIMITED ROLE FOR GLUCOCORTICOIDS</span><span class="headingEndMark"> — </span>We do not use glucocorticoids for the treatment of CAP in the outpatient setting because the potential harms likely outweigh any potential benefit. The benefit-to-risk ratio for glucocorticoid use appears to be greatest in critically ill patients with CAP and we do use glucocorticoids for selected critically ill patients. (See  <a class="medical medical_review" href="/z/d/html/7027.html" rel="external">"Treatment of community-acquired pneumonia in adults who require hospitalization", section on 'Adjunctive glucocorticoids'</a>.)</p><p>Acute exacerbations of chronic obstructive pulmonary disease (AECOPD) commonly co-occur with CAP. For outpatients with AECOPD and CAP, we treat with either inhaled or oral glucocorticoids depending on the severity of the AECOPD. In these circumstances, the use of glucocorticoids is for the treatment of AECOPD, not for the treatment of CAP. (See  <a class="medical medical_review" href="/z/d/html/1461.html" rel="external">"COPD exacerbations: Management", section on 'Home or office management of COPD exacerbations'</a>.)</p><p class="headingAnchor" id="H963777327"><span class="h1">DURATION OF THERAPY</span><span class="headingEndMark"> — </span>We treat most ambulatory patients with CAP for five days. Because of its long half-life, receiving <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a> at a dose of 500 mg daily can usually be treated for three days. Patients should be afebrile for ≥48 hours and clinically stable before therapy is discontinued. When this is achieved, the persistence of other symptoms (eg, dyspnea, cough) is not an indication to extend the course of antibiotic therapy.</p><p>Several meta-analyses evaluating patients with mild to moderate CAP found comparable clinical outcomes with less than seven days compared with more than seven days of antimicrobial therapy [<a href="#rid31">31-33</a>]. In one meta-analysis of 21 trials evaluating 4861 patients with CAP, no significant difference in clinical cure or relapse rates were detected when comparing antibiotic durations of ≤6 days versus durations of ≥7 days [<a href="#rid33">33</a>]. Mortality and serious adverse event rates were lower among those treated with shorter courses (risk ratio [RR] 0.52, 95% CI 0.33-0.82, and RR 0.73, 95% CI 0.55-0.97, respectively). Trials included in this analysis compared antibiotics from different classes and/or antibiotics with different half-lives, which may confound results. However, in a previous meta-analysis of five randomized trials evaluating adults with CAP comparing short (3 to 7 days) versus long (7 to 10 days) antibiotic courses, no differences in clinical success, relapse, or mortality were detected [<a href="#rid32">32</a>]. Most trials included in these meta-analyses evaluated hospitalized patients. Direct evidence supporting the optimal duration of therapy for outpatients with CAP is lacking [<a href="#rid34">34</a>].</p><p class="headingAnchor" id="H2175762629"><span class="h1">FOLLOW-UP CARE</span></p><p class="headingAnchor" id="H77310175"><span class="h2">Assessing clinical response</span><span class="headingEndMark"> — </span>All patients who are treated for CAP at home should have a follow-up visit or communication with a health care provider within 24 to 48 hours after being diagnosed to determine whether they are feeling better and to assess whether any complications of pneumonia have developed. Patients who have not responded to therapy after 48 to 72 hours should be re-evaluated. In addition, a later visit (eg, in one to four weeks) is often appropriate to ensure that symptoms continue to resolve and comorbid conditions (eg, heart failure, chronic obstructive pulmonary disease) have not worsened or newly developed.</p><p>Most patients with CAP begin to improve soon after the initiation of appropriate antibiotic therapy as evidenced by resolution of symptoms, physical findings, and laboratory signs of active infection. However, some symptoms persist as the patient convalesces  (<a class="graphic graphic_table graphicRef74599" href="/z/d/graphic/74599.html" rel="external">table 6</a>) [<a href="#rid35">35-37</a>]. This was illustrated in a study of sequential interviews in 134 ambulatory patients with CAP [<a href="#rid35">35</a>]. The median time to resolution ranged from 3 days for fever to 14 days for both cough and fatigue. At least one symptom (eg, cough, fatigue, dyspnea) was still present at 28 days in one-third of patients. In another report, 76 percent had at least one symptom at 30 days, most commonly fatigue, compared with 45 percent by history in the one month prior to the onset of CAP [<a href="#rid37">37</a>]. These symptoms are usually not sufficient to interfere with work, as illustrated in a review of 399 ambulatory patients with CAP in which the median time of return to work was 6 days even though one-third had at least one persistent symptom at 14 days [<a href="#rid36">36</a>]. (See  <a class="medical medical_review" href="/z/d/html/7016.html" rel="external">"Morbidity and mortality associated with community-acquired pneumonia in adults", section on 'Short-term morbidity and mortality'</a>.)</p><p class="headingAnchor" id="H16"><span class="h2">Chest radiograph</span><span class="headingEndMark"> — </span>We do not routinely obtain a follow-up chest radiograph in patients with CAP who have responded to therapy, as radiographic findings tend to lag behind clinical response [<a href="#rid10">10,38-41</a>]. This approach is similar to that outlined by the American Thoracic Society (ATS)/Infectious Diseases Society of America (IDSA), which recommends not obtaining a follow-up chest radiograph in patients whose symptoms have resolved within five to seven days [<a href="#rid10">10</a>].</p><p class="headingAnchor" id="H17"><span class="h2">Nonresolving CAP</span><span class="headingEndMark"> — </span>In a small minority of patients treated in the outpatient setting, initial symptoms will neither progress nor improve following empiric antibiotic treatment. We generally characterize these patients as having nonresolving pneumonia. Potential causes of nonresolving CAP include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Delayed clinical response</strong> – For some patients, particularly those with multiple comorbidities, more severe pneumonia, and infection with certain pathogens (eg, <em>S. pneumoniae)</em>, treatment response may be slow.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Loculated infection</strong> – Patients with complications such as lung abscess, empyema, or other closed-space infections may fail to improve clinically despite appropriate antibiotic selection. Such infections may require drainage and/or prolonged antibiotic treatment. (See  <a class="medical medical_review" href="/z/d/html/7030.html" rel="external">"Lung abscess in adults"</a> and  <a class="medical medical_review" href="/z/d/html/6702.html" rel="external">"Epidemiology, clinical presentation, and diagnostic evaluation of parapneumonic effusion and empyema in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bronchial obstruction</strong> – Bronchial obstruction (eg, by a tumor) can cause a postobstructive pneumonia that may fail to respond or may slowly respond to standard empiric antibiotic regimens for CAP.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogens that cause subacute/chronic CAP</strong> – <em>M. tuberculosis</em>, nontuberculous mycobacteria (eg, <em>Mycobacterium kansasii</em>), fungi (eg, <em>Histoplasma capsulatum</em>, <em>Blastomyces dermatitidis</em>), or less common bacteria (eg, <em>Nocardia</em> spp, <em>Actinomyces israelii</em>) can cause subacute or chronic pneumonia that may fail to respond or may incompletely respond to standard empiric antibiotic regimens for CAP.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Incorrect initial diagnosis</strong> – Failure to improve also raises the possibility of an alternate diagnosis (eg, malignancy or inflammatory lung disease). (See  <a class="medical medical_review" href="/z/d/html/117561.html" rel="external">"Overview of community-acquired pneumonia in adults", section on 'Differential diagnosis'</a>.)</p><p></p><p>Once a patient is characterized as having nonresolving CAP, a complete, new physical examination, laboratory evaluation, imaging studies, and microbiologic workup will be necessary to define the etiology of nonresolving CAP [<a href="#rid42">42</a>]. Initiation of workup for nonresolving CAP should not be automatically associated with a change in initial empiric antibiotic therapy. (See  <a class="medical medical_review" href="/z/d/html/6992.html" rel="external">"Nonresolving pneumonia"</a>.)</p><p class="headingAnchor" id="H3003372840"><span class="h1">PREVENTION</span></p><p class="headingAnchor" id="H600300773"><span class="h2">Pneumococcal and influenza vaccination</span><span class="headingEndMark"> — </span>Vaccination is an effective and important component of pneumonia prevention.</p><p class="bulletIndent1"><span class="glyph">●</span>Annual vaccination against seasonal influenza viruses is indicated for all patients (without contraindications). (See  <a class="medical medical_review" href="/z/d/html/7007.html" rel="external">"Seasonal influenza vaccination in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pneumococcal vaccination is indicated for all patients ≥65 years old and others with specific risk factors (eg, certain comorbidities including chronic heart, lung, and liver disease, immunocompromising conditions, and impaired splenic function). (See  <a class="medical medical_review" href="/z/d/html/7007.html" rel="external">"Seasonal influenza vaccination in adults"</a> and  <a class="medical medical_review" href="/z/d/html/7021.html" rel="external">"Pneumococcal vaccination in adults"</a>.) </p><p></p><p>Recommendations for other routine vaccinations are provided separately. (See  <a class="medical medical_review" href="/z/d/html/3884.html" rel="external">"Standard immunizations for nonpregnant adults"</a>.)</p><p class="headingAnchor" id="H2754919655"><span class="h2">Smoking cessation</span><span class="headingEndMark"> — </span>Smoking cessation should be a goal for patients with CAP who smoke, and we discuss this at the time of diagnosis and when providing follow-up care. (See  <a class="medical medical_review" href="/z/d/html/16634.html" rel="external">"Overview of smoking cessation management in adults"</a>.)</p><p class="headingAnchor" id="H62688334"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/104226.html" rel="external">"Society guideline links: Community-acquired pneumonia in adults"</a>.)</p><p class="headingAnchor" id="H20"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or email these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/15374.html" rel="external">"Patient education: Pneumonia in adults (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/z/d/html/4002.html" rel="external">"Patient education: Pneumonia in adults (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H21"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> – Community-acquired pneumonia (CAP) is one of the most common conditions encountered in the outpatient setting and can be associated with significant morbidity, particularly for older patients, smokers, and those with comorbidities and immunosuppression. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Principles of antibiotic selection</strong> – For all outpatients, our empiric regimens are designed to treat the most common bacterial causes of CAP, which include <em>Streptococcus pneumoniae</em>, <em>Haemophilus influenzae</em>, and atypical pathogens (ie, <em>Mycoplasma pneumoniae</em>, <em>Legionella pneumophila</em>, and <em>Chlamydia </em>pneumoniae)  (<a class="graphic graphic_table graphicRef72014" href="/z/d/graphic/72014.html" rel="external">table 3</a>). Coverage is expanded to better treat additional gram-negative pathogens (eg, beta-lactamase-producing <em>H. influenzae</em>, <em>Moraxella catarrhalis</em>) for those with comorbidities, older age, or recent antibiotic use. For patients with structural lung disease (eg, advanced chronic obstructive pulmonary disease), we also select a regimen that includes coverage for Enterobacteriaceae (eg, <em>Escherichia coli</em> and <em>Klebsiella </em>spp). (See <a class="local">'Empiric antibiotic treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>The importance of </strong><strong><em>S. pneumoniae</em></strong><em> </em>– The backbone of therapy is the beta-lactam, which primarily targets <em>S. pneumoniae</em> (the most common and virulent bacterial CAP pathogen). Among beta-lactams, high-dose <a class="drug drug_general" data-topicid="8673" href="/z/d/drug information/8673.html" rel="external">amoxicillin</a> and <a class="drug drug_general" data-topicid="8676" href="/z/d/drug information/8676.html" rel="external">amoxicillin-clavulanate</a> are preferred because they remain active against most strains of <em>S. pneumoniae</em>, while resistance rates among many other drug classes are rising. A macrolide or <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> is added to the beta-lactam to target atypical pathogens. (See <a class="local">'General approach'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Our approach to empiric antibiotic selection</strong> – Selection of a specific regimen depends on patient age, comorbidities (ie, chronic pulmonary, liver, heart, or kidney disease; cancer, diabetes mellitus, heart failure, alcohol use disorder), smoking status, and antibiotic use within the prior three months  (<a class="graphic graphic_algorithm graphicRef111829" href="/z/d/graphic/111829.html" rel="external">algorithm 2</a>).</p><p></p><p class="bulletIndent1">Modifications to these regimens may be needed based on patient travel and exposure history, local epidemiology (eg, outbreaks, family clusters), or when specific pathogens are suspected (eg, influenza viruses, community-acquired methicillin-resistant <em>Staphylococcus aureus</em>, <em>Mycobacterium tuberculosis</em>). (See <a class="local">'General approach'</a> above.)</p><p></p><p class="bulletIndent1">Our approach is generally similar to the American Thoracic Society/Infectious Diseases Society of America (ATS/IDSA) guidelines with few exceptions  (<a class="graphic graphic_table graphicRef142676" href="/z/d/graphic/142676.html" rel="external">table 4</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>For otherwise healthy outpatients aged &lt;65 years who have not used antibiotics within the prior three months, </strong>we suggest combination high-dose <a class="drug drug_general" data-topicid="8673" href="/z/d/drug information/8673.html" rel="external">amoxicillin</a> (1 g orally three times daily) plus either a macrolide or <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> rather than monotherapy with any of these agents (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). While the value of adding treatment for atypical pathogens is debated for this population, there is a potential morbidity benefit and the downside of a short course of therapy for most patients is low. (See <a class="local">'Healthy, age &lt;65 years, no recent antibiotic use'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>For outpatients aged ≥65 years, smokers, and patients with comorbidities and/or recent antibiotic use,</strong> we suggest <a class="drug drug_general" data-topicid="8676" href="/z/d/drug information/8676.html" rel="external">amoxicillin-clavulanate</a> (875 mg orally twice daily or the extended-release formulation at 2 g orally twice daily) plus either a macrolide or <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> over other regimens (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). We prefer the amoxicillin-clavulanate-based regimens over other regimens for its greater activity against <em>S. pneumoniae</em> and its favorable adverse effect profile. (See <a class="local">'Comorbidities, age 65 years or older, or recent antibiotic use'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Penicillin allergy</strong> – For patients who cannot use penicillins, combination therapy with a third-generation cephalosporin (eg, <a class="drug drug_general" data-topicid="9224" href="/z/d/drug information/9224.html" rel="external">cefpodoxime</a>) plus a macrolide or <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">doxycycline</a> is our preferred alternative. In general, patients with mild non-immunoglobulin E-mediated reactions (eg, maculopapular rash) to penicillin, and those known to tolerate cephalosporins, can generally safely use later-generation cephalosporins  (<a class="graphic graphic_table graphicRef117212" href="/z/d/graphic/117212.html" rel="external">table 7</a>). Patients with more severe penicillin hypersensitivity reactions should generally avoid empiric treatment with beta-lactams. (See <a class="local">'Preferred agents'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fluoroquinolones and other alternative agents</strong> – Fluoroquinolone monotherapy is equally effective as our preferred regimens; however, because of its adverse effect profile and potential for promoting drug resistance, we reserve fluoroquinolone use for patients who cannot tolerate these regimens. <a class="drug drug_general" data-topicid="122343" href="/z/d/drug information/122343.html" rel="external">Lefamulin</a> and <a class="drug drug_general" data-topicid="119253" href="/z/d/drug information/119253.html" rel="external">omadacycline</a> are newer agents and potential alternatives for selected patients who cannot tolerate beta-lactams (or other agents) and want to avoid the adverse effects associated with fluoroquinolones. However, clinical experience with these agents is limited, and there are contraindications to their use. (See <a class="local">'Preferred agents'</a> above and <a class="local">'Caveats for fluoroquinolones and macrolides'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Duration of therapy</strong> – A five-day course of antibiotic therapy is sufficient for most patients. In general, a follow-up visit or communication is indicated within a few days of starting treatment to ensure that the patient is improving. Although some symptoms may persist  (<a class="graphic graphic_table graphicRef74599" href="/z/d/graphic/74599.html" rel="external">table 6</a>), patients who have not clinically responded to treatment after 48 to 72 hours should be re-evaluated. (See <a class="local">'Duration of therapy'</a> above and <a class="local">'Follow-up care'</a> above.)</p><p></p><p class="headingAnchor" id="H2127735765"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>UpToDate gratefully acknowledges John G Bartlett, MD (deceased), who contributed on earlier versions of this topic and was a founding Editor-in-Chief for UpToDate in Infectious Diseases.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">File TM. Community-acquired pneumonia. Lancet 2003; 362:1991.</a></li><li><a class="nounderline abstract_t">Wunderink RG, Waterer GW. Clinical practice. Community-acquired pneumonia. N Engl J Med 2014; 370:543.</a></li><li><a class="nounderline abstract_t">Musher DM, Thorner AR. Community-acquired pneumonia. N Engl J Med 2014; 371:1619.</a></li><li><a class="nounderline abstract_t">Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44 Suppl 2:S27.</a></li><li><a class="nounderline abstract_t">American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171:388.</a></li><li><a class="nounderline abstract_t">Kalil AC, Metersky ML, Klompas M, et al. Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis 2016; 63:e61.</a></li><li><a class="nounderline abstract_t">Chalmers JD, Rother C, Salih W, Ewig S. Healthcare-associated pneumonia does not accurately identify potentially resistant pathogens: a systematic review and meta-analysis. Clin Infect Dis 2014; 58:330.</a></li><li><a class="nounderline abstract_t">Gross AE, Van Schooneveld TC, Olsen KM, et al. Epidemiology and predictors of multidrug-resistant community-acquired and health care-associated pneumonia. Antimicrob Agents Chemother 2014; 58:5262.</a></li><li><a class="nounderline abstract_t">Yap V, Datta D, Metersky ML. Is the present definition of health care-associated pneumonia the best way to define risk of infection with antibiotic-resistant pathogens? Infect Dis Clin North Am 2013; 27:1.</a></li><li><a class="nounderline abstract_t">Metlay JP, Waterer GW, Long AC, et al. Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med 2019; 200:e45.</a></li><li><a class="nounderline abstract_t">Shorr AF, Zilberberg MD, Reichley R, et al. Validation of a clinical score for assessing the risk of resistant pathogens in patients with pneumonia presenting to the emergency department. Clin Infect Dis 2012; 54:193.</a></li><li><a class="nounderline abstract_t">Webb BJ, Dascomb K, Stenehjem E, et al. Derivation and Multicenter Validation of the Drug Resistance in Pneumonia Clinical Prediction Score. Antimicrob Agents Chemother 2016; 60:2652.</a></li><li><a class="nounderline abstract_t">Malcolm C, Marrie TJ. Antibiotic therapy for ambulatory patients with community-acquired pneumonia in an emergency department setting. Arch Intern Med 2003; 163:797.</a></li><li><a class="nounderline abstract_t">File TM Jr, Marrie TJ. Does empiric therapy for atypical pathogens improve outcomes for patients with CAP? Infect Dis Clin North Am 2013; 27:99.</a></li><li><a class="nounderline abstract_t">File TM Jr, Eckburg PB, Talbot GH, et al. Macrolide therapy for community-acquired pneumonia due to atypical pathogens: outcome assessment at an early time point. Int J Antimicrob Agents 2017; 50:247.</a></li><li><a class="nounderline abstract_t">Pakhale S, Mulpuru S, Verheij TJ, et al. Antibiotics for community-acquired pneumonia in adult outpatients. Cochrane Database Syst Rev 2014; 2014:CD002109.</a></li><li><a class="nounderline abstract_t">File TM, Goldberg L, Das A, et al. Efficacy and Safety of Intravenous-to-oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-acquired Bacterial Pneumonia: The Phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) Trial. Clin Infect Dis 2019; 69:1856.</a></li><li><a class="nounderline abstract_t">Alexander E, Goldberg L, Das AF, et al. Oral Lefamulin vs Moxifloxacin for Early Clinical Response Among Adults With Community-Acquired Bacterial Pneumonia: The LEAP 2 Randomized Clinical Trial. JAMA 2019; 322:1661.</a></li><li><a class="nounderline abstract_t">Postma DF, van Werkhoven CH, van Elden LJ, et al. Antibiotic treatment strategies for community-acquired pneumonia in adults. N Engl J Med 2015; 372:1312.</a></li><li><a class="nounderline abstract_t">Eliakim-Raz N, Robenshtok E, Shefet D, et al. Empiric antibiotic coverage of atypical pathogens for community-acquired pneumonia in hospitalized adults. Cochrane Database Syst Rev 2012; :CD004418.</a></li><li><a class="nounderline abstract_t">Garin N, Genné D, Carballo S, et al. β-Lactam monotherapy vs β-lactam-macrolide combination treatment in moderately severe community-acquired pneumonia: a randomized noninferiority trial. JAMA Intern Med 2014; 174:1894.</a></li><li><a class="nounderline abstract_t">Kuster SP, Rudnick W, Shigayeva A, et al. Previous antibiotic exposure and antimicrobial resistance in invasive pneumococcal disease: results from prospective surveillance. Clin Infect Dis 2014; 59:944.</a></li><li><a class="nounderline abstract_t">Metersky ML, Ma A, Houck PM, Bratzler DW. Antibiotics for bacteremic pneumonia: Improved outcomes with macrolides but not fluoroquinolones. Chest 2007; 131:466.</a></li><li><a class="nounderline abstract_t">Martínez JA, Horcajada JP, Almela M, et al. Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2003; 36:389.</a></li><li><a class="nounderline abstract_t">Restrepo MI, Mortensen EM, Waterer GW, et al. Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia. Eur Respir J 2009; 33:153.</a></li><li><a class="nounderline abstract_t">Martin-Loeches I, Lisboa T, Rodriguez A, et al. Combination antibiotic therapy with macrolides improves survival in intubated patients with community-acquired pneumonia. Intensive Care Med 2010; 36:612.</a></li><li><a class="nounderline abstract_t">Asadi L, Sligl WI, Eurich DT, et al. Macrolide-based regimens and mortality in hospitalized patients with community-acquired pneumonia: a systematic review and meta-analysis. Clin Infect Dis 2012; 55:371.</a></li><li><a class="nounderline abstract_t">Raz-Pasteur A, Shasha D, Paul M. Fluoroquinolones or macrolides alone versus combined with β-lactams for adults with community-acquired pneumonia: Systematic review and meta-analysis. Int J Antimicrob Agents 2015; 46:242.</a></li><li><a class="nounderline abstract_t">Lee JS, Giesler DL, Gellad WF, Fine MJ. Antibiotic Therapy for Adults Hospitalized With Community-Acquired Pneumonia: A Systematic Review. JAMA 2016; 315:593.</a></li><li><a class="nounderline abstract_t">Chalmers JD, Al-Khairalla M, Short PM, et al. Proposed changes to management of lower respiratory tract infections in response to the Clostridium difficile epidemic. J Antimicrob Chemother 2010; 65:608.</a></li><li><a class="nounderline abstract_t">Li JZ, Winston LG, Moore DH, Bent S. Efficacy of short-course antibiotic regimens for community-acquired pneumonia: a meta-analysis. Am J Med 2007; 120:783.</a></li><li><a class="nounderline abstract_t">Dimopoulos G, Matthaiou DK, Karageorgopoulos DE, et al. Short- versus long-course antibacterial therapy for community-acquired pneumonia : a meta-analysis. Drugs 2008; 68:1841.</a></li><li><a class="nounderline abstract_t">Tansarli GS, Mylonakis E. Systematic Review and Meta-analysis of the Efficacy of Short-Course Antibiotic Treatments for Community-Acquired Pneumonia in Adults. Antimicrob Agents Chemother 2018; 62.</a></li><li><a class="nounderline abstract_t">López-Alcalde J, Rodriguez-Barrientos R, Redondo-Sánchez J, et al. Short-course versus long-course therapy of the same antibiotic for community-acquired pneumonia in adolescent and adult outpatients. Cochrane Database Syst Rev 2018; 9:CD009070.</a></li><li><a class="nounderline abstract_t">Metlay JP, Atlas SJ, Borowsky LH, Singer DE. Time course of symptom resolution in patients with community-acquired pneumonia. Respir Med 1998; 92:1137.</a></li><li><a class="nounderline abstract_t">Marrie TJ, Beecroft MD, Herman-Gnjidic Z. Resolution of symptoms in patients with community-acquired pneumonia treated on an ambulatory basis. J Infect 2004; 49:302.</a></li><li><a class="nounderline abstract_t">Fine MJ, Stone RA, Singer DE, et al. Processes and outcomes of care for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team (PORT) cohort study. Arch Intern Med 1999; 159:970.</a></li><li><a class="nounderline abstract_t">Bruns AH, Oosterheert JJ, Prokop M, et al. Patterns of resolution of chest radiograph abnormalities in adults hospitalized with severe community-acquired pneumonia. Clin Infect Dis 2007; 45:983.</a></li><li><a class="nounderline abstract_t">Mittl RL Jr, Schwab RJ, Duchin JS, et al. Radiographic resolution of community-acquired pneumonia. Am J Respir Crit Care Med 1994; 149:630.</a></li><li><a class="nounderline abstract_t">El Solh AA, Aquilina AT, Gunen H, Ramadan F. Radiographic resolution of community-acquired bacterial pneumonia in the elderly. J Am Geriatr Soc 2004; 52:224.</a></li><li><a class="nounderline abstract_t">Almirall J, Bolíbar I, Vidal J, et al. Epidemiology of community-acquired pneumonia in adults: a population-based study. Eur Respir J 2000; 15:757.</a></li><li><a class="nounderline abstract_t">Arancibia F, Ewig S, Martinez JA, et al. Antimicrobial treatment failures in patients with community-acquired pneumonia: causes and prognostic implications. Am J Respir Crit Care Med 2000; 162:154.</a></li></ol></div><div id="topicVersionRevision">Topic 7031 Version 75.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14683661" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Community-acquired pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24499212" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Clinical practice. Community-acquired pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25337751" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Community-acquired pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17278083" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15699079" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27418577" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24270053" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Healthcare-associated pneumonia does not accurately identify potentially resistant pathogens: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24957843" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Epidemiology and predictors of multidrug-resistant community-acquired and health care-associated pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23398862" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Is the present definition of health care-associated pneumonia the best way to define risk of infection with antibiotic-resistant pathogens?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31573350" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22109951" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Validation of a clinical score for assessing the risk of resistant pathogens in patients with pneumonia presenting to the emergency department.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26856838" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Derivation and Multicenter Validation of the Drug Resistance in Pneumonia Clinical Prediction Score.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12695270" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Antibiotic therapy for ambulatory patients with community-acquired pneumonia in an emergency department setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23398868" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Does empiric therapy for atypical pathogens improve outcomes for patients with CAP?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28599867" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Macrolide therapy for community-acquired pneumonia due to atypical pathogens: outcome assessment at an early time point.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25300166" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Antibiotics for community-acquired pneumonia in adult outpatients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30722059" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Efficacy and Safety of Intravenous-to-oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-acquired Bacterial Pneumonia: The Phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31560372" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Oral Lefamulin vs Moxifloxacin for Early Clinical Response Among Adults With Community-Acquired Bacterial Pneumonia: The LEAP 2 Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25830421" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Antibiotic treatment strategies for community-acquired pneumonia in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22972070" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Empiric antibiotic coverage of atypical pathogens for community-acquired pneumonia in hospitalized adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25286173" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : β-Lactam monotherapy vsβ-lactam-macrolide combination treatment in moderately severe community-acquired pneumonia: a randomized noninferiority trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24973312" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Previous antibiotic exposure and antimicrobial resistance in invasive pneumococcal disease: results from prospective surveillance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17296649" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Antibiotics for bacteremic pneumonia: Improved outcomes with macrolides but not fluoroquinolones.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12567294" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Addition of a macrolide to a beta-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18768577" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19953222" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Combination antibiotic therapy with macrolides improves survival in intubated patients with community-acquired pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22511553" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Macrolide-based regimens and mortality in hospitalized patients with community-acquired pneumonia: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26092096" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Fluoroquinolones or macrolides alone versus combined withβ-lactams for adults with community-acquired pneumonia: Systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26864413" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Antibiotic Therapy for Adults Hospitalized With Community-Acquired Pneumonia: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20179023" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Proposed changes to management of lower respiratory tract infections in response to the Clostridium difficile epidemic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17765048" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Efficacy of short-course antibiotic regimens for community-acquired pneumonia: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18729535" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Short- versus long-course antibacterial therapy for community-acquired pneumonia : a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29987137" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Systematic Review and Meta-analysis of the Efficacy of Short-Course Antibiotic Treatments for Community-Acquired Pneumonia in Adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30188565" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Short-course versus long-course therapy of the same antibiotic for community-acquired pneumonia in adolescent and adult outpatients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9926169" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Time course of symptom resolution in patients with community-acquired pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15474628" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Resolution of symptoms in patients with community-acquired pneumonia treated on an ambulatory basis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10326939" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Processes and outcomes of care for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team (PORT) cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17879912" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Patterns of resolution of chest radiograph abnormalities in adults hospitalized with severe community-acquired pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8118630" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Radiographic resolution of community-acquired pneumonia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14728631" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Radiographic resolution of community-acquired bacterial pneumonia in the elderly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10780770" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Epidemiology of community-acquired pneumonia in adults: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10903235" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Antimicrobial treatment failures in patients with community-acquired pneumonia: causes and prognostic implications.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
